Lepirudin | Buy Online | Anticoagulant Peptide Guide

A hematologist in Frankfurt, 1994. Her patient — a post-cardiac-surgery man in his sixties — is developing clots despite being on heparin. Not because heparin isn't working. Because heparin *is* working, paradoxically triggering an immune response that's activating his platelets and forming new, potentially fatal thromboses. Heparin-induced thrombocytopenia (HIT) — one of the most dangerous drug reactions in modern medicine, and one where the standard anticoagulant becomes the enemy.

She switches him to a new drug — barely approved, derived from the saliva of a medieval bloodsucker — and watches the clots stop forming within 24 hours.

That drug was lepirudin. And the story of how a 65-million-year-old protein from the European medicinal leech became a life-saving recombinant peptide anticoagulant is one of the most compelling in all of biochemical pharmacology.

---

The Discovery: From Leeches to Recombinant Protein

The medicinal leech, *Hirudo medicinalis*, has been used in medicine since ancient Egypt. But it wasn't until 1884 that Scottish physician John Berry Haycraft first identified that leech saliva contained a potent anticoagulant substance. He noticed that blood drawn from a leech bite simply wouldn't clot — not for hours. Something in that saliva was interfering with the coagulation cascade at a fundamental level.

For decades, the active principle remained mysterious. The structural work came slowly. By the 1950s, researchers had partially purified the anticoagulant protein and named it hirudin — from *Hirudo*, the leech genus. But isolating enough hirudin from actual leeches for clinical use was completely impractical. You'd need a warehouse full of leeches to treat a single patient.

The breakthrough arrived with the recombinant DNA revolution of the 1980s. In 1986, Fritz Markwardt's group at the Ernst Moritz Arndt University in Greifswald, East Germany, published the complete amino acid sequence of native hirudin. This opened the door to recombinant production. By the early 1990s, Hoechst AG (later Aventis) had successfully expressed a modified hirudin variant in *Saccharomyces cerevisiae* yeast — a 65-amino acid recombinant protein they called lepirudin (trade name: Refludan).

The key modification from native hirudin: lepirudin has leucine at position 1 instead of isoleucine, and critically, the tyrosine-63 sulfation present in native hirudin is absent. This desulfation slightly reduces thrombin-binding affinity but makes recombinant production in yeast dramatically more scalable — a necessary trade-off for manufacturing a drug in meaningful quantities.

The FDA approved lepirudin in 1998 specifically for anticoagulation in patients with HIT and associated thromboembolic disease. It became the first direct thrombin inhibitor approved in the United States — preceding bivalirudin and argatroban by several years in the HIT indication.

Hoechst Marion Roussel discontinued Refludan in 2012, citing manufacturing and commercial reasons rather than safety concerns. But lepirudin's mechanistic template continues to influence the design of next-generation anticoagulants, and the compound remains a critical research tool for understanding thrombin biology.

---

Chemical Identity: A 65-Residue Thrombin-Binding Machine

Lepirudin is a 65-amino acid single-chain polypeptide with a molecular weight of approximately 6,979 Da (6.98 kDa). That's small for a protein but large for a peptide by most definitions — it sits in the gray zone that makes it one of the most structurally interesting anticoagulant molecules ever characterized.

The structure features:

The compact disulfide-stabilized N-terminal domain provides structural rigidity and thermal stability. The C-terminal tail — particularly the Asp55-Phe56-Glu57-Glu58-Ile59-Pro60-Glu61-Glu62-Tyr63-Leu64-Gln65 sequence — is the primary recognition element for thrombin's fibrinogen-binding exosite (exosite I).

Stability profile: Lepirudin is stable at pH 7-8 in aqueous solution for extended periods when refrigerated at 2-8°C. It tolerates a moderate temperature range but degrades with repeated freeze-thaw cycling. In lyophilized form, it retains potency for years when stored below -20°C. This stability is a direct consequence of the disulfide scaffold — without those three disulfide bonds, the N-terminal domain would unfold and lose function rapidly.

One structural nuance that researchers often overlook: the absence of the tyrosine-63 sulfate group in lepirudin (compared to native hirudin) reduces its binding affinity for thrombin's exosite I by roughly 10-fold. The Ki for thrombin inhibition is approximately 0.2-0.3 nM for lepirudin versus ~0.02 nM for sulfated native hirudin. In practical terms, this is still extraordinarily tight binding — far tighter than any heparin-based anticoagulant — but it's a measurable difference that matters in comparative pharmacology.

---

Mechanism of Action: The World's Tightest Thrombin Lock

Primary Mechanism: Bivalent Thrombin Inhibition

Thrombin (Factor IIa) sits at the epicenter of the coagulation cascade. It converts fibrinogen to fibrin (forming the structural clot), activates platelets through PAR-1 and PAR-4 receptors, activates Factors V, VIII, XI, and XIII (amplifying its own generation), and activates protein C (providing feedback inhibition). Control thrombin, and you control clot formation.

Lepirudin achieves this control through a mechanism fundamentally different from heparin or warfarin. It's a direct thrombin inhibitor (DTI) — it binds to thrombin itself, not to cofactors or upstream enzymes.

But what makes lepirudin exceptional even among DTIs is its bivalent binding geometry. Lepirudin occupies *two distinct sites* on thrombin simultaneously:

1. The active site (catalytic site): The N-terminal globular domain of lepirudin inserts into thrombin's active site, blocking substrate access. The D-Phe-Pro motif equivalent structure physically occludes the S1-S3 subsites where fibrinogen normally binds for cleavage.

2. Exosite I (fibrinogen-binding exosite): The acidic C-terminal tail of lepirudin docks into thrombin's positively charged exosite I — the same surface that fibrinogen, thrombomodulin, and PAR receptors use for recognition. This electrostatic interaction is driven by complementary charge: lepirudin's acidic tail (net negative) against exosite I's basic patch (net positive).

The result of this bivalent engagement is a dissociation constant (Kd) of approximately 20-300 pM — meaning the lepirudin-thrombin complex is extraordinarily stable once formed. This is essentially irreversible inhibition under physiological conditions; the complex has a half-life of hours.

This bivalent mechanism confers a crucial advantage over univalent DTIs like argatroban (which only blocks the active site): lepirudin completely prevents thrombin from interacting with *any* of its substrates or receptors, not just fibrinogen cleavage. Platelet activation via PAR-1, Factor V activation, Factor VIII activation — all blocked simultaneously.

The Ki of lepirudin for thrombin (~0.2 nM) is roughly 10,000-fold tighter than heparin's indirect inhibition mechanism. This isn't a quantitative improvement — it's a qualitative shift in how anticoagulation works.

Secondary Pathways: Downstream Coagulation Effects

By locking thrombin out of the cascade, lepirudin produces a cascade of downstream effects that go beyond simple anticoagulation:

Fibrin formation arrest: With thrombin catalytic activity blocked, fibrinogen cannot be cleaved to fibrin monomers. No fibrin = no clot scaffold. This is the primary therapeutic effect.

Platelet activation inhibition: Thrombin is one of the most potent platelet activators known, acting through PAR-1 and PAR-4. Lepirudin blocks both pathways. This is particularly relevant in HIT, where heparin-PF4 complexes are already hyperactivating platelets via FcγRIIA receptors — lepirudin prevents the thrombin-mediated amplification of this platelet storm.

Thrombin-activatable fibrinolysis inhibitor (TAFI) pathway: Thrombin normally activates TAFI, which inhibits fibrinolysis (clot breakdown). By blocking thrombin, lepirudin indirectly promotes fibrinolytic activity — a secondary pro-thrombolytic effect that may help dissolve existing clots.

Factor XIII inhibition: Thrombin activates Factor XIII, which cross-links fibrin into a stable, plasmin-resistant mesh. Lepirudin prevents this cross-linking, making any fibrin that does form more susceptible to endogenous fibrinolysis.

Protein C pathway: Thrombin activates protein C (particularly when bound to thrombomodulin on endothelial cells). Lepirudin partially inhibits this pathway, which is a theoretical concern — protein C is anticoagulant — but in practice, the anticoagulant effect of direct thrombin inhibition vastly outweighs any reduction in protein C activation.

Systemic vs. Local Effects: Administration Route Matters

Lepirudin is administered exclusively by intravenous (IV) infusion or subcutaneous (SC) injection in clinical use. It cannot be taken orally — like all peptides of this size, it is completely degraded by gastrointestinal proteases before reaching systemic circulation.

IV administration produces immediate, predictable anticoagulation with a plasma half-life of approximately 1.3-1.5 hours in patients with normal renal function. Peak plasma concentrations are reached immediately. The dose-response relationship is highly linear, making titration predictable.

Subcutaneous administration produces a more delayed peak (2-4 hours) and lower peak concentrations, with bioavailability of approximately 85-90% — excellent for a peptide of this size. SC dosing has been studied for prophylactic applications and produces more stable plasma levels with less peak-trough variation than IV bolus dosing.

A critical pharmacokinetic reality: lepirudin is eliminated almost exclusively by the kidneys. Glomerular filtration and tubular secretion account for ~35% of clearance; proteolytic degradation accounts for the remainder. In patients with renal impairment, half-life extends dramatically — up to 2 days in severe renal failure. This makes renal function monitoring absolutely essential during lepirudin use.

The activated partial thromboplastin time (aPTT) is the standard monitoring parameter, with target ranges of 1.5-2.5× the normal aPTT baseline used in most clinical protocols. The aPTT-response relationship is linear up to concentrations of approximately 2 μg/mL, above which the aPTT becomes disproportionately prolonged relative to the anticoagulant effect.

---

The Evidence Base: What the Research Actually Shows

HIT and Thrombosis Prevention

The landmark clinical evidence for lepirudin comes from two prospective studies known as HAT-1 and HAT-2 (Heparin-Associated Thrombocytopenia), conducted by the HAT Investigators group and published between 1999 and 2001.

HAT-1 (Greinacher et al., 1999, *New England Journal of Medicine*): This prospective cohort study enrolled 82 patients with confirmed HIT (defined as >50% platelet count decrease during heparin therapy with laboratory confirmation). Lepirudin was administered as a 0.4 mg/kg IV bolus followed by continuous infusion of 0.15 mg/kg/hour, adjusted to maintain aPTT 1.5-2.5× baseline. The primary composite endpoint — new thromboembolic complications, limb amputation, or death — occurred in 25% of lepirudin-treated patients versus 52% in the historical control group (patients who received no alternative anticoagulation). The absolute risk reduction of 27% was statistically significant (p<0.01). Critically, no new thromboembolic events occurred in patients who achieved therapeutic aPTT levels within the first 24 hours.

HAT-2 (Greinacher et al., 2000): Extended the HAT-1 findings in 139 HIT patients across multiple centers. The composite endpoint occurred in 29% of lepirudin patients versus 52% in historical controls. Major bleeding occurred in 17% — a rate that prompted subsequent dosing revisions, particularly in renally impaired patients.

Cardiopulmonary Bypass and Cardiac Surgery

Patients with HIT who require cardiac surgery present an extreme anticoagulation challenge: cardiopulmonary bypass (CPB) requires full anticoagulation, but heparin cannot be used. Lepirudin's predictable pharmacokinetics and ability to be monitored by ecarin clotting time (ECT) — which is more sensitive than aPTT at high concentrations — made it the agent of choice for this indication.

Koster et al. (2000, *Journal of Thoracic and Cardiovascular Surgery*): In 13 HIT patients undergoing cardiac surgery with CPB, lepirudin was administered as a 0.25 mg/kg bolus before bypass, with additional boluses to maintain ECT >250 seconds. All surgeries were completed without thromboembolic complications on bypass. Two patients required reoperation for bleeding — highlighting the challenge of reversibility (there is no antidote for lepirudin). The study established ECT as the monitoring parameter of choice for high-concentration lepirudin use.

Vanholder et al. (2001): Examined lepirudin for anticoagulation during hemodialysis in HIT patients — a particularly challenging situation because these patients have renal failure (extending lepirudin half-life dramatically). Using drastically reduced doses (0.005-0.01 mg/kg/hr), adequate anticoagulation of the dialysis circuit was achieved without systemic accumulation, though close aPTT monitoring every session was required.

Antithrombotic Effects in Acute Coronary Syndrome

Before its discontinuation, lepirudin was investigated as an anticoagulant for acute coronary syndrome (ACS), where direct thrombin inhibition has theoretical advantages over heparin — particularly the ability to inhibit clot-bound thrombin, which heparin cannot reach.

OASIS-2 (Organization to Assess Strategies for Ischemic Syndromes, 1999): This large randomized trial compared lepirudin (0.4 mg/kg bolus + 0.15 mg/kg/hr for 72 hours) to unfractionated heparin in 10,141 patients with unstable angina or non-ST-elevation MI. The primary endpoint — death, MI, or refractory angina at 7 days — occurred in 3.6% of lepirudin patients versus 4.2% of heparin patients (relative risk reduction 15%, p=0.057). The result narrowly missed statistical significance, but the trend consistently favored lepirudin. Major bleeding rates were similar (1.2% vs 0.9%). This study suggested that more potent thrombin inhibition produces modest but real clinical benefit in ACS, though not enough to displace heparin in a non-HIT population where cost and familiarity favor heparin.

Immunogenicity and Antibody Formation

One of the most pharmacologically interesting aspects of lepirudin research concerns its immunogenicity — the development of anti-hirudin antibodies in treated patients.

Greinacher et al. (2003, *Blood*): In a prospective analysis of 196 lepirudin-treated HIT patients, 74 (38%) developed anti-hirudin IgG antibodies. In most patients, these antibodies *paradoxically enhanced* lepirudin's anticoagulant effect by forming drug-antibody complexes that reduced renal clearance, prolonging half-life. In approximately 4% of patients, however, the antibodies caused anaphylaxis upon re-exposure — a critical safety finding that led to contraindication of lepirudin re-administration. This immunogenicity profile is unique among anticoagulants and represents one of the most compelling reasons why researchers designing next-generation hirudin analogs have focused heavily on reducing immunogenic epitopes.

---

Complete Dosing Guide for Research Applications

*Note: The following information is presented for research purposes only. Lepirudin requires precise monitoring and medical supervision. All clinical use should be under physician guidance with appropriate aPTT or ECT monitoring.*

Standard Clinical Protocol (HIT Indication)

The original FDA-approved dosing for HIT, based on HAT-1/HAT-2 data:

Subsequent HAT-3 data and post-marketing experience led to revised lower doses now considered standard:

Dosing Table by Renal Function

Subcutaneous Dosing Protocol (Research/Prophylaxis)

For prophylactic applications studied in research settings:

Reconstitution and Storage

Reconstitution: Lepirudin lyophilate is typically supplied as 50 mg vials. Reconstitute with:

Stability after reconstitution:

Storage of lyophilate: Store at 2-8°C. Lyophilized product stable for 2-3 years if properly refrigerated. Do not freeze the reconstituted solution.

---

Stacking Strategies: Lepirudin in Combined Anticoagulation Research

Protocol 1: Lepirudin + Antiplatelet Therapy for HIT with ACS

In HIT patients who also have acute coronary syndrome, thrombin inhibition alone may be insufficient — platelet activation through non-thrombin pathways (ADP, TXA2) continues. The research-supported approach combines:

Mechanistic rationale: Lepirudin blocks thrombin-mediated platelet activation (PAR-1, PAR-4) while aspirin blocks TXA2-mediated activation. These are complementary, non-overlapping mechanisms. The combination produces more complete platelet inhibition than either agent alone. Bleeding risk is additive, requiring aPTT targets at the lower end of the therapeutic range.

Protocol 2: Lepirudin + Thrombolytic for Acute DVT/PE in HIT

For HIT patients with massive pulmonary embolism or iliofemoral DVT requiring thrombolysis:

Mechanistic rationale: Thrombolytics (alteplase) convert plasminogen to plasmin, dissolving fibrin. But residual thrombin bound within the clot is released as the clot dissolves — this thrombin can trigger rebound thrombosis. Lepirudin inhibits this released clot-bound thrombin, preventing rethrombosis after successful lysis.

Protocol 3: Lepirudin for Extracorporeal Circuit Anticoagulation

For HIT patients requiring ECMO, hemodialysis, or cardiac surgery:

Note: Lepirudin has no antidote. In the event of overdose or life-threatening bleeding, management relies on hemodialysis (removes some lepirudin), fresh frozen plasma, and time.

---

Safety Deep Dive

Common Side Effects

Bleeding is the dominant adverse effect and occurs on a spectrum from minor to life-threatening:

The bleeding risk is strongly correlated with:

1. Renal function (most important factor — accumulation in renal failure)

2. Age >65 (reduced renal clearance, more fragile vasculature)

3. Recent surgery or trauma

4. Concurrent antiplatelet agents

5. aPTT levels above 2.5× baseline

Rare but Serious Risks

Anaphylaxis and hypersensitivity reactions: The most clinically significant rare risk. Anti-hirudin antibodies develop in ~38% of treated patients (Greinacher 2003). Re-exposure in antibody-positive patients carries a 1-3% risk of anaphylaxis, which can be fatal. This is a hard contraindication to re-treatment — lepirudin should never be administered to a patient with known prior exposure without first testing for anti-hirudin antibodies.

Paradoxical anticoagulant enhancement: In antibody-positive patients, the drug-antibody complex has reduced renal clearance, effectively increasing the plasma half-life and anticoagulant effect. This can cause unexpected aPTT prolongation and bleeding in patients who appeared stable. aPTT must be monitored continuously in re-exposed patients.

Intracranial hemorrhage: Rare (<1%) but catastrophic. Risk factors include hypertension, prior stroke, and aPTT >3× baseline. The lack of an antidote makes intracranial bleeding from lepirudin particularly dangerous.

Thrombocytopenia: Distinct from HIT itself — lepirudin-induced thrombocytopenia has been reported rarely and is likely immune-mediated via anti-hirudin antibodies.

Contraindications

Absolute contraindications:

Relative contraindications:

---

Lepirudin vs. Alternative Direct Thrombin Inhibitors

Lepirudin was the first DTI approved in the US but is now discontinued commercially. Understanding how it compares to its successors — and to hirudin family members — is essential for researchers choosing anticoagulant tools.

The key differentiator: Lepirudin's bivalent binding produces the tightest thrombin inhibition of any approved anticoagulant (Ki ~0.2 nM). This is simultaneously its greatest strength (near-complete thrombin suppression) and its greatest weakness (no antidote, prolonged effect in renal failure).

Bivalirudin represents the most direct structural successor to lepirudin — also bivalent, but enzymatically cleaved by thrombin itself within the active site (the Arg-Pro bond in the active-site-binding sequence is hydrolyzed), creating a built-in auto-inactivation mechanism. This gives bivalirudin a 25-minute half-life even in renal failure — a major safety advantage over lepirudin's 1.5-hour (normal) to 48-hour (severe renal failure) half-life range.

Argatroban occupies a different niche: hepatically eliminated, making it the DTI of choice in HIT patients with severe renal failure. But its univalent binding (active site only) means it cannot block exosite I-mediated thrombin functions — including clot-bound thrombin activation of PAR receptors.

Dabigatran etexilate (Pradaxa) is the oral DTI — a prodrug converted to dabigatran after absorption. Its convenience is unmatched, but it's not approved for HIT (clinical data insufficient) and requires renal dose adjustment as stringently as lepirudin.

---

Lepirudin in the Context of Broader Peptide Anticoagulant Research

Lepirudin's legacy extends well beyond its commercial life. It established that a recombinant peptide could be a viable pharmaceutical anticoagulant — overcoming the production challenges that had blocked hirudin from clinical use for decades. This proof of concept accelerated research into the broader field of peptide-based anticoagulants.

The hirudin family itself continues to yield new compounds. Native hirudin variants (HV1, HV2, HV3) differ primarily in their C-terminal sequences and show slightly different exosite I binding kinetics. Researchers have used these variants to map the precise geometry of the thrombin-exosite I interaction at atomic resolution — work that's been invaluable for structure-based drug design.

Beyond hirudin, lepirudin's success validated the exosite I targeting strategy that has since been applied to entirely synthetic peptide anticoagulants. Short peptides derived from the fibrinogen Aα chain (which naturally binds exosite I) have been developed as competitive inhibitors — though none has yet matched lepirudin's affinity.

The thrombin exosite II — a heparin-binding site distinct from exosite I — represents another peptide targeting opportunity that lepirudin research helped illuminate. Aptamers (nucleic acid-based binders) targeting exosite II have been developed as research tools, partly because lepirudin's exosite I-targeting established the proof of concept that exosite-directed inhibition is pharmacologically viable.

For researchers interested in the GHK-Cu or BPC-157 literature on wound healing, it's worth noting that thrombin biology intersects with tissue repair — thrombin cleaves fibrinogen to create the provisional matrix in which healing occurs. Understanding how DTIs like lepirudin modify this provisional matrix has implications for wound healing research, though this remains largely unexplored territory.

---

What's Coming Next: Open Questions in Lepirudin and DTI Research

Lepirudin's commercial discontinuation in 2012 didn't close the research questions it opened — it left several unresolved.

The immunogenicity problem: 38% antibody formation remains the single biggest unresolved issue with hirudin-based anticoagulants. Which specific epitopes on lepirudin trigger IgG formation? Can PEGylation or glycosylation of the C-terminal tail reduce immunogenicity without abolishing exosite I binding? Several groups have published preliminary work suggesting that PEGylated hirudin analogs show dramatically reduced antibody formation in animal models while maintaining >80% of the anticoagulant potency. These modified analogs have not yet entered clinical trials.

Clot-bound thrombin inhibition: Lepirudin can inhibit clot-bound thrombin — a capability that unfractionated heparin lacks entirely. The clinical significance of this in ACS was suggested but not proven in OASIS-2. A definitive trial comparing lepirudin to bivalirudin specifically for clot-bound thrombin inhibition in STEMI patients has never been conducted. With bivalirudin's self-inactivating mechanism, it actually *releases* thrombin from the active site after cleavage — theoretically less effective than lepirudin at sustained clot-bound thrombin inhibition.

Pediatric HIT: HIT in children is rare but catastrophic, and pediatric dosing data for lepirudin is extremely limited — mostly case reports and small series. The pharmacokinetic behavior in children with developing renal function differs substantially from adults. Argatroban has largely displaced lepirudin in pediatric HIT due to hepatic elimination, but the mechanistic superiority of bivalent inhibition in this population remains an open question.

Topical and local delivery: Could lepirudin be used topically — for example, on medical device surfaces or in wound dressings — to provide local anticoagulation without systemic effects? The high water solubility and stability of lepirudin make this theoretically attractive. Preliminary work on lepirudin-coated ECMO circuits showed reduced thrombosis versus heparin-coated circuits in animal models, but human data doesn't exist.

Combination with direct oral anticoagulants (DOACs): As DOACs have displaced warfarin for most indications, the question of transitioning from lepirudin (or its research-grade equivalents) to long-term DOAC therapy in post-HIT patients has practical importance. The optimal timing and overlap strategy for this transition remains incompletely defined.

Structural biology applications: Lepirudin's extraordinarily tight thrombin binding makes it an invaluable crystallography tool. The thrombin-hirudin crystal structure (PDB: 2HNT) resolved at 2.3 Å remains one of the most cited serine protease co-crystal structures in the literature — used routinely for structure-based drug design of both anticoagulants and thrombin-activating compounds.

---

Where to Find Lepirudin for Research

Since Refludan's commercial discontinuation, lepirudin is available through specialty chemical and peptide suppliers as a research-grade reagent. It's used in:

Researchers sourcing lepirudin should prioritize vendors offering HPLC purity >95% and mass spectrometry confirmation of the correct 65-residue sequence with intact disulfide bonds. Disulfide bond integrity is critical — reduced (linearized) lepirudin loses thrombin-binding activity almost completely.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com